October 27,Buchang PharmaceuticalDisclosure of the report for the third quarter of 2021, achieved in the first three quartersOperating income11.377 billion yuan, an increase of 1.18% year-on-year;Net profit1.274 billion yuan, a year-on-year decrease of 8.73%. Among them, in the third quarter of 2021,Buchang PharmaceuticalRealized operating income of 3.99 billion yuan, a year-on-year decrease of 5.17%; net profit attributable to the parent company was 328 million yuan, a year-on-year decrease of 33.66%.
As of the end of the third quarter,Buchang PharmaceuticalThe total assets were 23.304 billion yuan, which was 22.886 billion yuan at the end of the previous year, an increase of 1.83%; attributable to listed companiesshareholderThe owner’s equity of 14.407 billion yuan was 13.715 billion yuan at the end of the previous year, an increase of 5.05%.
For the third quarterPerformanceBuchang Pharmaceutical explained that it was mainly due to the year-on-year decrease in operating income of Danhong injection due to policy impacts during the reporting period, the year-on-year increase in management expenses due to the commissioning of production equipment in the subsidiary Zhejiang Huapai, and the year-on-year increase in external donations during the reporting period And so on.
On the same day, Buchang PharmaceuticalannouncementAccording to the report, the company and Rizhao Sanqi formally signed the “Regarding Northern Health Medical Big Data Technology Co., Ltd.Equity transfer“Agreement”, the two parties agreed that the delivery of 1% equity of Northern Health will be initiated within 30 days after the signing of this agreement, and the transaction price will be 0 yuan.
It is understood that Northern Health was established in July last year with a registered capital of 2.5 billion yuan. Its legal person is Dai Zhong. It is a health care digital service operator led by a number of provincial enterprises. The major shareholder of the company is Lianren Health Medical Big Data Technology Co., Ltd., with a shareholding ratio of 48.6%. In addition, the provincial enterprises Shandong Development Investment Holding Group Co., Ltd., Shandong Energy Medical Health Investment Co., Ltd., and Shandong Finance Development Investment Co., Ltd. The company holds 8% of the shares, and the private company Yinfeng Xinbai Health Big Data Co., Ltd. holds 8.4%. Buchang Pharmaceutical holds a total of 1% of the company’s equity, corresponding to a registered capital of 25 million yuan.
The takeover party, Rizhao Sanqi, is a comprehensive production and export enterprise that produces disposable medical devices, sanitary products and non-woven daily-use products. The company was established in 1993 with a registered capital of 10 million yuan and the legal person is Wang Changshen. From the perspective of shareholding structure, Wang Changshen holds 96% of its shares and is the company’s largest shareholder. Wang Changhua and Xu Congjuan each hold 2% of its shares.
From the perspective of financial status, the company’s unaudited financial data shows that as of December 31, 2020, Rizhao Sanqi had total assets of 1.201 billion yuan, total liabilities of 349 million yuan, and net assets of 852 million yuan. Last year, it achieved operating income. 1.833 billion yuan, with a net profit of 821 million yuan.
As of the close of October 27, Buchang Pharmaceuticals closed at 17.68 yuan per share, a decline of 2.70%, and the total market value was about 20.18 billion yuan.
(Source: CDC Finance)
.